반응식
Cl[C:2]1[N:3]=[C:4]([N:12]2[CH2:17][CH2:16][O:15][CH2:14][CH2:13]2)[C:5]2[S:10][C:9](I)=[CH:8][C:6]=2[N:7]=1.[NH2:18][C:19]1[CH:20]=[C:21](B(O)O)[CH:22]=[C:23]([C:25]([O:27][CH3:28])=[O:26])[CH:24]=1.CC1(C)C(C)(C)OB([C:40]2[CH:48]=[CH:47][CH:46]=[C:45]3[C:41]=2[CH:42]=[N:43][NH:44]3)O1>>[NH:44]1[C:45]2[C:41](=[C:40]([C:2]3[N:3]=[C:4]([N:12]4[CH2:17][CH2:16][O:15][CH2:14][CH2:13]4)[C:5]4[S:10][C:9]([C:21]5[CH:22]=[C:23]([CH:24]=[C:19]([NH2:18])[CH:20]=5)[C:25]([O:27][CH3:28])=[O:26])=[CH:8][C:6]=4[N:7]=3)[CH:48]=[CH:47][CH:46]=2)[CH:42]=[N:43]1참가 물질
4
반응물 3
생성물 1
실험 절차
2-Chloro-6-iodo-4-morpholinothieno[3,2-d]pyrimidine 19 (50 mg) was coupled to 3-amino-5-methoxycarbonylphenyl boronic acid, and then reacted with 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole via General Procedure F. The product was purified by reverse phase HPLC to yield 5.2 mg of 300. MS. (Q1) 487.1 (M)+
후처리
- customThe product was purified by reverse phase HPLC
출처 및 근거
- ORD 기록
- ord-55742bb1e2fa4404857516a8dac668d7
- 출처 데이터셋
- uspto-grants-2010_12
- 특허 번호
- US07846929B2
연결된 노트
불러오는 중…